Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 update narrowed the timeline for the start of two Phase 3 studies of SQVK2735 in obesity, and while the toplines from Phase 3 won’t come until late 2026/2027, the Phase 2 Oral VK2735 topline in the second half of this year and IND of amylin are key near-term catalysts, the analyst tells investors in a research note. Truist adds however that it is removing VK2809 from its sum of parts valuation model on reduced visibility on path forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Roblox downgraded, Pinterest upgraded: Wall Street’s top analyst calls
- Viking Therapeutics price target lowered to $96 from $109 at B. Riley
- Viking Therapeutics price target lowered to $70 from $120 at Maxim
- Viking Therapeutics initiated with a Neutral at Citi
- Viking Therapeutics Reports Strong Trials and Financial Health